Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tonix Pharmaceuticals Holding (TNXP) Enterprise Value (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Enterprise Value data on record, last reported at -$97.6 million in Q3 2025.

  • For Q3 2025, Enterprise Value fell 245.69% year-over-year to -$97.6 million; the TTM value through Sep 2025 reached -$97.6 million, down 245.69%, while the annual FY2024 figure was -$98.8 million, 295.93% down from the prior year.
  • Enterprise Value reached -$97.6 million in Q3 2025 per TNXP's latest filing, up from -$101.5 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$4.2 million in Q2 2024 and bottomed at -$131.7 million in Q1 2025.
  • Average Enterprise Value over 3 years is -$54.4 million, with a median of -$28.2 million recorded in 2024.
  • Peak YoY movement for Enterprise Value: surged 90.21% in 2024, then crashed 2342.25% in 2025.
  • A 3-year view of Enterprise Value shows it stood at -$24.9 million in 2023, then tumbled by 295.93% to -$98.8 million in 2024, then rose by 1.19% to -$97.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Enterprise Value were -$97.6 million in Q3 2025, -$101.5 million in Q2 2025, and -$131.7 million in Q1 2025.